FPT-155

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameFPT-155

Drug Alias NameFPT-155CD80-Fc

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsT-cell-specific surface glycoprotein CD28 agonistsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1T-cell-specific surface glycoprotein CD28Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaSouth Korea

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesFive Prime Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFive Prime Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A